Physician profile
Mario Vukic
NPI 1043287865
$309,865.38
in general payments reported to CMS, 2019-2025
25 companies · $149K in 2025
The $149K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.18 · 2021: $300 · 2022: $6,906 · 2023: $46K · 2024: $108K · 2025: $149K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $234K · Travel and Lodging: $45K · Food and Beverage: $12K · Consulting Fee: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $234,448.50 |
| Travel and Lodging | $45,084.28 |
| Food and Beverage | $11,952.52 |
| Consulting Fee | $11,160.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $145,919.85 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Ucb, INC. | $76,147.74 | 2019-2025 | Rystiggo, Zilbrysq, Briviact |
| Alexion Pharmaceuticals, INC. | $46,653.28 | 2021-2025 | Ultomiris |
| Amgen INC. | $21,177.36 | 2021-2025 | Uplizna, Aimovig |
| Janssen Biotech, INC. | $17,915.86 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $402.24 | 2021-2025 | Austedo Xr, Austedo, Ajovy |
| Abbvie INC. | $272.52 | 2021-2025 | Botox, Qulipta |
| Novartis Pharmaceuticals Corporation | $229.17 | 2021-2025 | |
| Pfizer INC. | $218.81 | 2021-2025 | |
| Tg Therapeutics, INC. | $151.46 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $148.99 | 2025 | |
| Emd Serono, INC. | $128.18 | 2022-2024 | Mavenclad |
| Celgene Corporation | $81.46 | 2021-2025 | Zeposia |
| Grifols USA, LLC | $60.90 | 2023-2025 | Gamunex-C |
| Csl Behring | $59.86 | 2021-2023 | Hizentra |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $53.45 | 2022-2023 | |
| Lundbeck LLC | $49.96 | 2022-2024 | Vyepti, Rexulti |
| Janssen Pharmaceuticals, INC | $43.52 | 2021-2022 | |
| Biogen, INC. | $35.91 | 2021 | |
| Alnylam Pharmaceuticals INC. | $29.03 | 2021-2025 | Amvuttra |
| Takeda Pharmaceuticals U.S.A., INC. | $19.11 | 2025 | Hyqvia |
| Lilly USA, LLC | $17.58 | 2023 | Reyvow, Emgality |
| Impel Pharmaceuticals INC. | $16.96 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $16.62 | 2023 | Nuedexta |
| Biohaven Pharmaceuticals, INC. | $15.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mario Vukic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.